Arlington, MA, United States of America

Trevor Percival Castor

This inventor holds 38 USPTO granted patents and 36 published patent applications and 3 EPO patents, primarily in Nanotechnology Therapeutics. Top assignees: Aphios Corporation, Louisiana State University and Agricultural & Mechanical College, Arphios Corporation. Active years: 1995-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Trevor Percival Castor. Retrieved from https://idiyas.com/inventor/trevor-percival-castor

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 38 

% Patents Active = 97.4

 

Average Co-Inventor Count = 1.4

ph-index = 12

Forward Citations = 505(Granted Patents)


Company Filing History:


Years Active: 1995-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
mRNA Vaccine
HIV Therapeutics
Drug Delivery
Nanosomes
Polymer Microspheres
Viral Inactivation
Cancer Treatment
Neurodegenerative Disease
Biologically-Derived Materials
Supercritical Fluids
Therapeutic Proteins
Cannabinoid Formulations
38 patents (USPTO):Explore Patents

Title: Innovations and Contributions of Trevor Percival Castor

Introduction

Trevor Percival Castor, based in Arlington, Massachusetts, is a noted inventor with an impressive portfolio of 37 patents to his name. His work primarily focuses on advancements in cannabinoid manufacturing and innovative therapeutic solutions for various diseases, including HIV-1.

Latest Patents

Among his latest patents is a significant innovation regarding the "Thermal Conversion of CBDA and Other Carboxylic Cannabinoids." This invention addresses the manufacturing of pharmaceutical-grade CBD and cannabinoids, adhering to the current Good Manufacturing Practices (cGMP) set by the US FDA. It aims to enhance cannabinoid production for clinical trials across various indications pursued by institutions such as the NIH. This method sheds light on the transformation of Cannabigerolic Acid (CBGA) and its carboxylic acid derivatives, facilitating the efficient derivation of medically relevant cannabinoids.

Another noteworthy patent is focused on "CCR5 and CD4 siRNA-Targeted Phospholipid Nanosomes Therapeutics for Treatment of HIV-1 and Other Diseases." This invention centers on the nanoencapsulation of siRNA within phospholipid nanosomes, targeting enhanced delivery to affected organs and cells in humans and animals. The design of novel siRNAs aims to downregulate critical receptors, including CCR5 and CD4, contributing to advancements in therapeutic strategies against viral infections.

Career Highlights

Trevor has made substantial contributions through his work at Aphios Corporation, where he has collaborated on various innovative projects in the biotechnology field. His dedication to research and development has allowed him to influence the landscape of cannabinoid therapies and disease management protocols effectively.

Collaborations

Throughout his career, Trevor has worked with notable professionals, including colleagues Glenn T Hong and Jonathan Steven Alexander. These collaborations have further enriched his contributions to the fields of biotechnology and pharmaceuticals.

Conclusion

Trevor Percival Castor is a prominent inventor whose work continues to impact the realms of cannabinoid research and innovative therapies. His extensive patent portfolio showcases his commitment to advancing medical science and improving health outcomes through innovative solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…